Recursion Pharmaceuticals developed a promising artificial intelligence (AI) platform for drug discovery and development. The company's clinical-stage pipeline is just the tip of the iceberg of its ...
Through the funding and collaboration with Nvidia, Recursion plans to develop new AI models for drug discovery on the Nvidia DGX Cloud—billed as “AI-training-as-a-service” software. (iambuff/ ...
Recursion Pharmaceuticals Stock Could Be a 10-Bagger, but Only if It Comes Through on This Big Claim
Recursion hopes to transform the healthcare industry with its innovative drug discovery platform. The small company has gained the interest of Nvidia, which has invested in the business. Together, the ...
At a job interview on Friday, I had to write code, and one of the things that came up when we were talking about implementation of a concept was recursion. The director of the group said to me "Don't ...
Recursion Pharmaceuticals, Inc. leverages AI to accelerate drug discovery, offering both a licensing platform and an internal drug development pipeline. RXRX faces heavy competition, ongoing operating ...
Monday - Friday, 6:00 - 7:00 PM ET In a Friday interview with CNBC's Jim Cramer, Recursion Pharmaceuticals CEO Chris Gibson discussed how his company is using artificial intelligence and machine ...
Scientists in Spain have implemented recursive least squares (RLS) algorithms for anomaly detection in PV systems and have found they can provide “more realistic and meaningful assessment” than ...
Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. LONDON — In the year-plus since ...
Researchers at the University of Tübingen have found via experimentation that crows are capable of understanding the concept of recursion. In their paper published in the journal Science Advances, ...
When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. (RXRX) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4 ...
Recursion Pharmaceuticals reported Q3 2026 revenue of US$18.55 million and a net loss of US$119.04 million, while ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results